In a product-focused funding climate, groundbreaking science alone fails to attract capital without clear commercial line of sight. Founders must work backward from patient volume, duration of use, and adoption barriers, dividing quantifiable value by development cost and timeline to demonstrate a five- to tenfold return multiple.

Instead of waiting years for separate pediatric studies, Syndax integrated children into its initial adult clinical trials. This highly unusual approach, combined with creating child-friendly formulations, enabled them to bring novel medicines to both adults and children simultaneously, addressing a critical need much faster.

While hype cycles focus on novel areas, significant value exists in established markets like hypertension. By targeting refractory patient populations with high unmet needs (e.g., the 20% of hypertension patients not properly treated), biotechs can create valuable assets with novel mechanisms in fields that appear saturated.

Airway selected Bronchopulmonary Dysplasia (BPD) for its lead program due to strong preclinical data, a unique mechanism in infants (arrested lung development), and zero approved treatments. This strategic choice created a clear regulatory path, a strong competitive advantage, and addressed a significant unmet medical need.

In today's tightened market, a brilliant scientific platform isn't enough to secure investment. Investors have shifted to a product-focused lens, requiring founders to present a clear, detailed pathway from their idea to an approved drug. This includes defining the unmet medical need and outlining the proposed clinical trial design from day one.

The Orphan Drug Act successfully incentivized R&D for rare diseases. A similar policy framework is needed for common, age-related diseases. Despite their massive potential markets, these indications suffer from extremely high failure rates and costs. A new incentive structure could de-risk development and align commercial goals with the enormous societal need for longevity.

The lack of new drugs for pre-term babies is a market failure. For three decades, progress has been crippled by a dual challenge: venture capital funds avoiding pediatric studies and regulatory agencies lacking recent experience in evaluating neonatal treatments, creating a vicious cycle of stagnation.

Liz Parrish realized that creating drugs for children faced immense regulatory hurdles. By targeting aging in adults, she could de-risk gene therapies and develop treatments also applicable to childhood illnesses, creating a faster, more viable path to helping kids.

Instead of pursuing broad, expensive trials common in areas like cardiovascular disease, smaller biotechs can succeed by focusing. They use imaging, genetics, and proximal biomarkers to identify and enroll a highly specific patient population whose disease is still modifiable, enabling much smaller and more targeted clinical trials.